WO2007075672A3 - Marqueurs pour le pronostic du cancer - Google Patents

Marqueurs pour le pronostic du cancer Download PDF

Info

Publication number
WO2007075672A3
WO2007075672A3 PCT/US2006/048411 US2006048411W WO2007075672A3 WO 2007075672 A3 WO2007075672 A3 WO 2007075672A3 US 2006048411 W US2006048411 W US 2006048411W WO 2007075672 A3 WO2007075672 A3 WO 2007075672A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer markers
prognostic cancer
prognostic
cancer
prognosis
Prior art date
Application number
PCT/US2006/048411
Other languages
English (en)
Other versions
WO2007075672A2 (fr
Inventor
U Margaretha Wallon
George C Prendergast
Karen A Knudsen
Original Assignee
Lankenau Inst Medical Res
U Margaretha Wallon
George C Prendergast
Karen A Knudsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Inst Medical Res, U Margaretha Wallon, George C Prendergast, Karen A Knudsen filed Critical Lankenau Inst Medical Res
Publication of WO2007075672A2 publication Critical patent/WO2007075672A2/fr
Publication of WO2007075672A3 publication Critical patent/WO2007075672A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés, des kits et des compositions permettant de diagnostiquer, d'évaluer le pronostic ou de surveiller la progression d'un cancer chez un sujet, en particulier d'un cancer du sein.
PCT/US2006/048411 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer WO2007075672A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75361905P 2005-12-23 2005-12-23
US60/753,619 2005-12-23

Publications (2)

Publication Number Publication Date
WO2007075672A2 WO2007075672A2 (fr) 2007-07-05
WO2007075672A3 true WO2007075672A3 (fr) 2008-06-26

Family

ID=38218531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048411 WO2007075672A2 (fr) 2005-12-23 2006-12-20 Marqueurs pour le pronostic du cancer

Country Status (1)

Country Link
WO (1) WO2007075672A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
SG10201505769PA (en) 2010-07-27 2015-09-29 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
KR101621036B1 (ko) * 2011-03-27 2016-05-13 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트
EP3164417A1 (fr) 2014-07-01 2017-05-10 Pfizer Inc. Diabodies hétérodimères bispécifiques et leurs utilisations
CN108064244B (zh) 2014-11-14 2021-09-17 诺华股份有限公司 抗体药物缀合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723581A (en) * 1995-05-05 1998-03-03 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1)
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US20030166021A1 (en) * 1997-06-06 2003-09-04 The Wistar Institute Of Anatomy And Biology Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor
WO2002008765A2 (fr) * 2000-07-26 2002-01-31 Stanford University Marqueurs basocellulaires du cancer du sein et leurs utilisations
US20030086934A1 (en) * 2000-07-26 2003-05-08 David Botstein Basal cell markers in breast cancer and uses thereof
WO2002097395A2 (fr) * 2001-05-31 2002-12-05 Chiron Corporation Utilisation de p-cadherine comme cible dans la therapie anticancereuse
US20040121343A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated Markers for differential diagnosis and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG M. ET AL.: "Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4", ONCOGENE, vol. 14, 1997, pages 2767 - 2774 *

Also Published As

Publication number Publication date
WO2007075672A2 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2006074430A3 (fr) Biomarqueurs de melanome
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2008030986A3 (fr) Diagnostic et classification moléculaires de mélanome malin
WO2007082154A3 (fr) Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4
CA2602088C (fr) Marqueurs biologiques du cancer de l'ovaire et du cancer de l'endometre
WO2006012646A3 (fr) Marqueurs de cancers amacr
WO2007064776A3 (fr) Marqueurs du cancer du sein
WO2009115615A3 (fr) Détection et pronostic du cancer du col de l’utérus
WO2004061410A3 (fr) Biomarqueurs seriques du cancer du poumon
HK1154407A1 (en) Markers for prenatal diagnosis and monitoring
WO2007095644A3 (fr) reactifs et procedes pour le pronostic et la stadification pathologique d'un cancer
EP2485047A3 (fr) Procédés et combinaisons de marqueurs pour dépister la prédisposition au cancer du poumon
WO2009055820A3 (fr) Biomarqueurs de protéines salivaires pour le cancer de la bouche de l'homme
WO2006047412A3 (fr) Procedes et necessaires permettant de detecter une instabilite genomique de cellules germinales
WO2010033371A3 (fr) Marqueurs moléculaires pour les carcinomes pulmonaires et colorectaux
WO2006063133A3 (fr) Biomarqueurs pour maladie intestinale inflammatoire
WO2006034032A3 (fr) Marqueurs biologiques destines au cancer du sein
WO2007075672A3 (fr) Marqueurs pour le pronostic du cancer
WO2007056049A3 (fr) Profilage moleculaire de cancer
WO2006031986A3 (fr) Procedes et compositions de diagnostic de maladie neoplasique
WO2006102526A3 (fr) Identification de biomarqueurs par un profilage de proteines de serum
WO2007106762A3 (fr) Biomarqueurs de la maladie d'alzheimer et méthodes d'utilisation
WO2008086002A3 (fr) Génotype slco1b3
WO2010009171A3 (fr) Activation de src pour déterminer le pronostic du cancer et en tant que cible pour la thérapie du cancer
EP1829967A4 (fr) Procede de diagnostic de lymphome malin et d'estimation du pronostic associe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848889

Country of ref document: EP

Kind code of ref document: A2